62 / 89
62
dexametasona. Os eventos adversos mais comuns
na talidomida são constipação (42,1%), fadiga
(23,9%), astenia (13,9%), anemia (13,1%), tontura
(12,9%), lombalgia (12,1%), e nausea (11%), e na
dexametasona são fadiga (22,6%), insonia (19,4%),
constipação (16,1%), edema (14,5%), diarreia
(14,5%), artralgia (12,1%), astenia (12,1%), anemia
(11,3%), dor óssea (10,5%) e bronquite (10,5%).
Grade 3 or 4 treatment-emergent adverse events
were reported in 38% of patients treated with
dexamethasone and 44% of patients treated with
thalidomide, and appeared to be dose-related (32%
in THAL 100, 38% in THAL 200, and 60% in THAL
400). The incidence of grade 3 or 4 hematologic
adverse events was low in all treatment groups
(Table 4). The most commonly reported grade 3 or 4
treatment-emergent
adverse
events
were
neutropenia (THAL 6% and DEX 0%), anemia
(THAL 6% and DEX 4%), fatigue (THAL 5% and
DEX 2%), and pneumonia (THAL 4% and DEX 4%).
Os eventos adversos grau 3 ou 4 na talidomida são
neutropenia
febril,
constipação,
neuropatia
periférica, eventos tromboembólicos, arritmias
cardíacas, não havendo diferença significativa entre
a talidomida e a dexametasona
70
(
A
).
Pacientes com MM, com ausência de resposta
ou refratariedade ao tratamento com melfalano,